Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01332019
Registration number
NCT01332019
Ethics application status
Date submitted
24/03/2011
Date registered
8/04/2011
Date last updated
13/01/2017
Titles & IDs
Public title
Long-Term Safety and Efficacy Study of Peginterferon Beta-1a
Query!
Scientific title
A Dose-Frequency Blinded, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis
Query!
Secondary ID [1]
0
0
2010-024477-39
Query!
Secondary ID [2]
0
0
105MS302
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
ATTAIN
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Relapsing Multiple Sclerosis
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - peginterferon beta-1a
Experimental: peginterferon beta-1a Q4W - 125 µg peginterferon beta-1a administered by subcutaneous (SC) injection every 4 weeks (Q4W) for at least 2 years and up to 4 years.
Experimental: peginterferon beta-1a Q2W - 125 µg peginterferon beta-1a administered by SC injection every 2 weeks (Q2W) for at least 2 years and up to 4 years.
Treatment: Drugs: peginterferon beta-1a
Administered as specified in the treatment arm
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of Participants Experiencing Adverse Events (AEs) Serious AEs, and Discontinuations Due to AEs
Query!
Assessment method [1]
0
0
AE: any untoward medical occurrence that did not necessarily have a causal relationship with study treatment. SAE: any untoward medical occurrence that at any dose: resulted in death; in the view of the Investigator, placed the participant at immediate risk of death (a life threatening event); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in a congenital anomaly/birth defect; any other medically important event that, in the opinion of the Investigator, could have jeopardized the participant or may have required intervention to prevent one of the other outcomes listed in the definition above. Data collected after Amendment 3 took effect were excluded for participants enrolled into study 105MS302 on every 4 week dosing, but not excluded for participants enrolled on every 2 week dosing.
Query!
Timepoint [1]
0
0
up to 4 years
Query!
Primary outcome [2]
0
0
Number of Participants With Potentially Clinically Significant Hematology Laboratory Abnormalities
Query!
Assessment method [2]
0
0
Data collected after Amendment 3 took effect were excluded for participants enrolled into study 105MS302 on every 4 week dosing, but not excluded for participants enrolled on every 2 week dosing.
Query!
Timepoint [2]
0
0
up to 4 years
Query!
Primary outcome [3]
0
0
Number of Participants With Shifts From Baseline: Liver Function Laboratory Values
Query!
Assessment method [3]
0
0
Shift to low includes normal to low, high to low, and unknown to low. Shift to high includes normal to high, low to high, and unknown to high. For participants who switched to alternative MS medications, data after switch and 14 days after last dose of study treatment are excluded. Data collected after Amendment 3 took effect were excluded for participants enrolled into study 105MS302 on every 4 week dosing, but not excluded for participants enrolled on every 2 week dosing. ALT=alanine aminotransferase; AST=aspartate aminotransferase; GGT=gamma-glutamyl transferase.
Query!
Timepoint [3]
0
0
Baseline (BIIB017 Treatment Baseline from Study 105MS301) up to 4 years
Query!
Primary outcome [4]
0
0
Number of Participants With Shifts From Baseline: Kidney Function and Other Blood Chemistry
Query!
Assessment method [4]
0
0
Shift to low includes normal to low, high to low, and unknown to low. Shift to high includes normal to high, low to high, and unknown to high. For participants who switched to alternative MS medications, data after switch and 14 days after last dose of study treatment are excluded. Data collected after Amendment 3 took effect were excluded for participants enrolled into study 105MS302 on every 4 week dosing, but not excluded for participants enrolled on every 2 week dosing. TSH=thyroid stimulating hormone.
Query!
Timepoint [4]
0
0
Baseline (BIIB017 Treatment Baseline from Study 105MS301) up to 4 years
Query!
Primary outcome [5]
0
0
Number of Participants With Shifts From Baseline: Urinalysis
Query!
Assessment method [5]
0
0
Shift to low includes normal to low, high to low, and unknown to low. Shift to high/positive includes normal to high/positive, low to high/positive, negative to high/positive, and unknown to high/positive. For participants who switched to alternative MS medications, data after switch and 14 days after last dose of study treatment are excluded. Data collected after Amendment 3 took effect were excluded for participants enrolled into study 105MS302 on every 4 week dosing, but not excluded for participants enrolled on every 2 week dosing. Pos=positive; RBC=red blood cells; WBC=white blood cells.
Query!
Timepoint [5]
0
0
Baseline (BIIB017 Treatment Baseline from Study 105MS301) up to 4 years
Query!
Secondary outcome [1]
0
0
Annualized Relapse Rate (ARR)
Query!
Assessment method [1]
0
0
Relapses are defined as new or recurrent neurologic symptoms not associated with fever or infection, lasting at least 24 hours, and accompanied by new objective neurological findings upon examination by the examining neurologist. The annualized relapse rate is calculated as the total number of relapses occurred during the period for all participants, divided by the total number of person-years followed in the period.
Query!
Timepoint [1]
0
0
up to 4 years
Query!
Secondary outcome [2]
0
0
Percentage of Participants Who Relapsed
Query!
Assessment method [2]
0
0
Relapses are defined as new or recurrent neurologic symptoms not associated with fever or infection, lasting at least 24 hours, and accompanied by new objective neurological findings upon examination by the examining neurologist. New or recurrent neurologic symptoms that occur less than 30 days following the onset of a relapse were considered part of the same relapse. Participants who did not experience a relapse prior to switching to alternative MS medications, withdrew from study, or Amendment 3 (A3) took effect were censored at the time of switch/withdrawal/A3 effective date.
Query!
Timepoint [2]
0
0
Up to 4 years
Query!
Secondary outcome [3]
0
0
Number of New or Newly Enlarging T2 Hyperintense Lesions
Query!
Assessment method [3]
0
0
The total number of new or newly enlarging T2 hyperintense lesions (from Study 105MS302 Baseline) as assessed by magnetic resonance imaging (MRI). Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.
Query!
Timepoint [3]
0
0
Week 48, Week 96
Query!
Secondary outcome [4]
0
0
Number of New Active Lesions
Query!
Assessment method [4]
0
0
The number of new active lesions as assessed by MRI. Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.
Query!
Timepoint [4]
0
0
Week 48, Week 96
Query!
Secondary outcome [5]
0
0
Number of New T1 Hypointense Lesions
Query!
Assessment method [5]
0
0
The total number of new T1 hypointense lesions as assessed by MRI.
Query!
Timepoint [5]
0
0
Week 48, Week 96
Query!
Secondary outcome [6]
0
0
Number of Gd-Enhancing Lesions
Query!
Assessment method [6]
0
0
The number of Gd-enhancing lesions as assessed by MRI. Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.
Query!
Timepoint [6]
0
0
Baseline (start of 105MS302), Week 48, Week 96
Query!
Secondary outcome [7]
0
0
Volume of T2 Hyperintense Lesions
Query!
Assessment method [7]
0
0
The volume of T2 hyperintense lesions as assessed by MRI. Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.
Query!
Timepoint [7]
0
0
Baseline (start of 105MS302), Week 48, Week 96
Query!
Secondary outcome [8]
0
0
Volume of T1 Hypointense Lesions
Query!
Assessment method [8]
0
0
The volume of T1 hypointense lesions as assessed by MRI. Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.
Query!
Timepoint [8]
0
0
Baseline (start of 105MS302), Week 48, Week 96
Query!
Secondary outcome [9]
0
0
Volume of Gd-Enhancing Lesions
Query!
Assessment method [9]
0
0
The volume of Gd-enhancing lesions as assessed by MRI. Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.
Query!
Timepoint [9]
0
0
Baseline (start of 105MS302), Week 48, Week 96
Query!
Secondary outcome [10]
0
0
Percentage Change of Whole Brain Volume
Query!
Assessment method [10]
0
0
Percentage change of whole brain volume as assessed by MRI. Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.
Query!
Timepoint [10]
0
0
Baseline (start of 105MS302), Week 48, Week 96
Query!
Secondary outcome [11]
0
0
Change From Baseline in Expanded Disability Status Scale (EDSS)
Query!
Assessment method [11]
0
0
Change from Baseline in disability as measured by the Expanded Disability Status Scale (EDSS). The EDSS measures the disability status of people with multiple sclerosis on a scale that ranges from 0 to 10. The range of main categories include (0) = normal neurologic exam; to (5) = ambulatory without aid or rest for 200 meters; disability severe enough to impair full daily activities; to (10) = death due to MS. Data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.
Query!
Timepoint [11]
0
0
Baseline (start of 105MS302), Weeks 12, 24, 48, 72, 96, 120, 144, 168
Query!
Secondary outcome [12]
0
0
Time to Sustained Disability Progression
Query!
Assessment method [12]
0
0
Estimated proportion of participants with progression and time to progression based on the Kaplan-Meier product limit method. Sustained disability progression is defined as: at least a 1.0 point increase on the EDSS from 105MS302 baseline EDSS = 1.0 that is sustained for 24 weeks, or at least a 1.5 point increase on the EDSS from 105MS302 baseline EDSS = 0 that is sustained for 24 weeks. The EDSS measures the disability status of people with multiple sclerosis on a scale that ranges from 0 to 10. The range of main categories include (0) = normal neurologic exam; to (5) = ambulatory without aid or rest for 200 meters; disability severe enough to impair full daily activities; to (10) = death due to MS. Participants were censored at the time of withdrawal/switch/A3 effective date if they withdrew from study, switched to alternative MS medication, or Amendment 3 took effect without a progression.
Query!
Timepoint [12]
0
0
Weeks 12, 24, 28, 72, 96, 120, 144, 168
Query!
Secondary outcome [13]
0
0
Change From Baseline in Symbol Digit Modalities Test (SDMT)
Query!
Assessment method [13]
0
0
SDMT is a screening test for cognitive impairment. Participants are given 90 seconds in which to pair specific numbers with given geometric figures using a key. Scores range from 0 (worst) to 110 (best).
Query!
Timepoint [13]
0
0
Baseline (start of 105MS302), Weeks 24, 48, 72, 96, 120, 144, 168
Query!
Secondary outcome [14]
0
0
Change From Baseline in Multiple Sclerosis Impact Scale (MSIS)-29 Physical Score
Query!
Assessment method [14]
0
0
The 29-item MSIS-29 is a disease-specific participant-reported outcome measure that has been developed and validated to examine the physical and psychological impact of MS from a patient's perspective; it measures 20 physical items and 9 psychological items. Responses use a 5-point Likert scale ranging from 1 to 5. All questions are to be answered. The physical well being assessment portion of the MSIS-29 consists of 20 questions in which participants rate the impact of MS on their day-to-day life during the past two weeks from 1=no impact to 5=extreme impact for a total score of 20-100. A lower total score indicates less physically-related impact while a higher total score indicates greater physically-related impact on a participant's functioning. Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.
Query!
Timepoint [14]
0
0
Baseline (start of 105MS302), Weeks 24, 48, 72, 96, 120, 144, 168
Query!
Secondary outcome [15]
0
0
Change From Baseline in 12-Item Short Form Health Survey (SF-12) Mental Component Score (MCS)
Query!
Assessment method [15]
0
0
The SF-12 is a multipurpose short form survey with 12 questions, all selected from the SF-36 Health Survey. The questions were combined, scored, and weighted to create two scales that provide glimpses into mental and physical functioning and overall health-related-quality of life. MCS computed using the scores of 12 questions and range from 0 to 100, where a 0 score indicates the lowest level of health and 100 indicates the highest level of health. Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.
Query!
Timepoint [15]
0
0
Baseline (start of 105MS302), Weeks 24, 48, 72, 96, 120, 144, 168
Query!
Secondary outcome [16]
0
0
Change From Baseline in SF-12 Physical Component Score (PCS)
Query!
Assessment method [16]
0
0
The SF-12 is a multipurpose short form survey with 12 questions, all selected from the SF-36 Health Survey. The questions were combined, scored, and weighted to create two scales that provide glimpses into mental and physical functioning and overall health-related-quality of life. PCS was computed using the scores of 12 questions and range from 0 to 100, where a 0 score indicates the lowest level of health and 100 indicates the highest level of health. Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.
Query!
Timepoint [16]
0
0
Baseline (start of 105MS302), Weeks 24, 48, 72, 96, 120, 144, 168
Query!
Secondary outcome [17]
0
0
Change From Baseline in Euro Quality of Life (EQ-5D) Index Score
Query!
Assessment method [17]
0
0
The EQ-5D is a participant-answered questionnaire scoring 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Scores of 1, 2, or 3 are possible responses for each of 5 questions (1=no problems, 2=some problems, 3=severe problems). A scoring formula developed by the EuroQol Group is then used to assign utility values for each participant's Health State Profile. A summary index score (EQ-5D index score) is derived from the 5 questions by conversion with this scoring formula and a table of scores. EQ-5D Summary Index values ranged from -0.6 (worst health state) to 1.00 (perfect health state). Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.
Query!
Timepoint [17]
0
0
Baseline (start of 105MS302), Weeks 24, 48, 72, 96, 120, 144, 168
Query!
Secondary outcome [18]
0
0
Change From Baseline in EQ-5D Visual Analogue Scale (VAS)
Query!
Assessment method [18]
0
0
The EQ-5D VAS records the participant's self-rated health on a scale from 0-100 where 100 is the 'best imaginable health state' and 0 is the 'worst imaginable health state.' The scale was normalized to a scale of 0 to 1, with higher values indicating a better health state. Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.
Query!
Timepoint [18]
0
0
Baseline (start of 105MS302), Weeks 24, 48, 72, 96, 120, 144, 168
Query!
Secondary outcome [19]
0
0
Number of Relapses Requiring IV Steroid Use
Query!
Assessment method [19]
0
0
Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.
Query!
Timepoint [19]
0
0
up to 4 years
Query!
Secondary outcome [20]
0
0
Number of MS-Related Hospitalizations
Query!
Assessment method [20]
0
0
Observed data after participants switched to alternative MS medications or after Amendment 3 took effect are excluded.
Query!
Timepoint [20]
0
0
up to 4 years
Query!
Secondary outcome [21]
0
0
Summary of Participant-Reported Treatment Satisfaction: How Tolerable or Intolerable Do You Find the Medication?
Query!
Assessment method [21]
0
0
Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant's perception of treatment satisfaction at the end of each year of treatment. For the question "How tolerable or intolerable do you find the medication?" answers were numerically rated from 1 (extremely intolerable) to 10 (extremely tolerable). Data after Amendment 3 took effect are excluded.
Query!
Timepoint [21]
0
0
Year 1, Year 2, Year 3
Query!
Secondary outcome [22]
0
0
Summary of Participant-Reported Treatment Satisfaction: How Convenient or Inconvenient Is It to Take Your Medication as Instructed?
Query!
Assessment method [22]
0
0
Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant's perception of treatment satisfaction at the end of each year of treatment. For the question "How convenient or inconvenient is it to take your medication as instructed?" answers were numerically rated from 1 (extremely inconvenient) to 10 (extremely convenient). Data after Amendment 3 took effect are excluded.
Query!
Timepoint [22]
0
0
Year 1, Year 2, Year 3
Query!
Secondary outcome [23]
0
0
Summary of Participant-Reported Treatment Satisfaction: How Convenient or Inconvenient Is It to Take Your Medication Every 2 Weeks?
Query!
Assessment method [23]
0
0
Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant's perception of treatment satisfaction at the end of each year of treatment. For the question "How convenient or inconvenient is it to take your medication every 2 weeks?" answers were numerically rated from 1 (extremely inconvenient) to 10 (extremely convenient). Data after Amendment 3 took effect are excluded.
Query!
Timepoint [23]
0
0
Year 1, Year 2, Year 3
Query!
Secondary outcome [24]
0
0
Summary of Participant-Reported Treatment Satisfaction: Overall, How Satisfied or Dissatisfied Are You With This Medication?
Query!
Assessment method [24]
0
0
Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant's perception of treatment satisfaction at the end of each year of treatment. For the question "Overall, how satisfied or dissatisfied are you with this medication?" answers were numerically rated from 1 (extremely dissatisfied) to 10 (extremely satisfied). Data after Amendment 3 took effect are excluded.
Query!
Timepoint [24]
0
0
Year 1, Year 2, Year 3
Query!
Secondary outcome [25]
0
0
Summary of Participant-Reported Treatment Satisfaction: How Satisfied or Dissatisfied Are You With the Injection Frequency (Every 2 Weeks)?
Query!
Assessment method [25]
0
0
Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant's perception of treatment satisfaction at the end of each year of treatment. For the question "How satisfied or dissatisfied are you with the injection frequency (every 2 weeks)?" answers were numerically rated from 1 (extremely dissatisfied) to 10 (extremely satisfied). Data after Amendment 3 took effect are excluded.
Query!
Timepoint [25]
0
0
Year 1, Year 2, Year 3
Query!
Secondary outcome [26]
0
0
Summary of Participant-Reported Treatment Satisfaction: How Likely Would You Be to Continue to Use This Medication?
Query!
Assessment method [26]
0
0
Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant's perception of treatment satisfaction at the end of each year of treatment. For the question "How likely would you be to continue to use this medication?" answers were numerically rated from 1 (extremely unlikely) to 10 (extremely likely). Data after Amendment 3 took effect are excluded.
Query!
Timepoint [26]
0
0
Year 1, Year 2, Year 3
Query!
Secondary outcome [27]
0
0
Summary of Participant-Reported Treatment Satisfaction: This Medication Enables Me to Focus More on Myself and My Family Rather Than My MS.
Query!
Assessment method [27]
0
0
Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant's perception of treatment satisfaction at the end of each year of treatment. For the statement "This Medication Enables Me to Focus More on Myself and My Family Rather Than My MS," answers were numerically rated from 1 (strongly disagree) to 10 (strongly agree). Data after Amendment 3 took effect are excluded.
Query!
Timepoint [27]
0
0
Year 1, Year 2, Year 3
Query!
Secondary outcome [28]
0
0
Summary of Participant-Reported Treatment Satisfaction: This Medication Makes It Easy For Me to Carry Out My Daily Responsibilities.
Query!
Assessment method [28]
0
0
Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant's perception of treatment satisfaction at the end of each year of treatment. For the statement "This medication makes it easy for me to carry out my daily responsibilities (ie, going to work, doing household chores or caring for my family)," answers were numerically rated from 1 (strongly disagree) to 10 (strongly agree). Data after Amendment 3 took effect are excluded.
Query!
Timepoint [28]
0
0
Year 1, Year 2, Year 3
Query!
Secondary outcome [29]
0
0
Summary of Participant-Reported Treatment Satisfaction: The Twice a Month Dosing Makes It More Convenient for Me to Travel/Vacation.
Query!
Assessment method [29]
0
0
Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant's perception of treatment satisfaction at the end of each year of treatment. For the statement "The twice a month dosing makes it more convenient for me to travel/vacation," answers were numerically rated from 1 (strongly disagree) to 10 (strongly agree). Data after Amendment 3 took effect are excluded.
Query!
Timepoint [29]
0
0
Year 1, Year 2, Year 3
Query!
Secondary outcome [30]
0
0
Summary of Participant-Reported Treatment Satisfaction: The Twice a Month Dosing Enables Me to Be More Spontaneous and Flexible.
Query!
Assessment method [30]
0
0
Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant's perception of treatment satisfaction at the end of each year of treatment. For the statement "The twice a month dosing enables me to be more spontaneous and flexible," answers were numerically rated from 1 (strongly disagree) to 10 (strongly agree). Data after Amendment 3 took effect are excluded.
Query!
Timepoint [30]
0
0
Year 1, Year 2, Year 3
Query!
Secondary outcome [31]
0
0
Summary of Participant-Reported Treatment Satisfaction: This Medication Improves My Self-Confidence and Self-Reliance.
Query!
Assessment method [31]
0
0
Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant's perception of treatment satisfaction at the end of each year of treatment. For the statement "This medication improves my self-confidence and self-reliance," answers were numerically rated from 1 (strongly disagree) to 10 (strongly agree). Data after Amendment 3 took effect are excluded.
Query!
Timepoint [31]
0
0
Year 1, Year 2, Year 3
Query!
Secondary outcome [32]
0
0
Summary of Participant-Reported Treatment Satisfaction: I Am Satisfied With the Dosing Frequency of This Medication.
Query!
Assessment method [32]
0
0
Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant's perception of treatment satisfaction at the end of each year of treatment. For the statement "I am satisfied with the dosing frequency (2 times per month) of this medication" answers were numerically rated from 1 (strongly disagree) to 10 (strongly agree). Data after Amendment 3 took effect are excluded.
Query!
Timepoint [32]
0
0
Year 1, Year 2, Year 3
Query!
Secondary outcome [33]
0
0
Summary of Participant-Reported Treatment Satisfaction: Over the Past 4 Weeks, Did You Miss Any of Your Injections?
Query!
Assessment method [33]
0
0
Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant's perception of treatment satisfaction at the end of each year of treatment. For the question "Over the past 4 weeks, did you miss any of your injections?" answer choices were given as "none missed," "miss 1 injection," or "miss 2 injections." Data after Amendment 3 took effect are excluded.
Query!
Timepoint [33]
0
0
Year 1, Year 2, Year 3
Query!
Secondary outcome [34]
0
0
Summary of Participant-Reported Treatment Satisfaction: Main Reason for Missed Injections
Query!
Assessment method [34]
0
0
Participants completed a Treatment Satisfaction Questionnaire composed of a range of 14 questions regarding the participant's perception of treatment satisfaction at the end of each year of treatment. For the question "Main reason for missed injections?" answer choices were given as "medication side effects," "injection pain," "forget to take medication," "tired of taking injections," "don't think medication is working," or "other." Data after Amendment 3 took effect are excluded.
Query!
Timepoint [34]
0
0
Year 1, Year 2, Year 3
Query!
Eligibility
Key inclusion criteria
Key
- Must have completed the study treatment and visit schedule through Week 96 in Study
105MS301 (NCT00906399).
Key
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
65
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Subjects exceeding more than 6 weeks since completion of the Week 96 visit of Study
105MS301 (NCT00906399).
- Subjects with any clinically significant laboratory abnormalities, malignancies,
cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic,
pulmonary, neurologic, dermatologic, psychiatric, renal, or other major disease
- Pregnant or nursing women.
NOTE: Other protocol-defined Inclusion/Exclusion criteria may apply.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/04/2011
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/10/2015
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1077
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Georgia
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Kentucky
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Maryland
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
North Carolina
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Ohio
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Tennessee
Query!
Country [7]
0
0
Belgium
Query!
State/province [7]
0
0
Sint-Truiden
Query!
Country [8]
0
0
Bulgaria
Query!
State/province [8]
0
0
Plovdiv
Query!
Country [9]
0
0
Bulgaria
Query!
State/province [9]
0
0
Sofia
Query!
Country [10]
0
0
Canada
Query!
State/province [10]
0
0
Ontario
Query!
Country [11]
0
0
Canada
Query!
State/province [11]
0
0
Quebec
Query!
Country [12]
0
0
Chile
Query!
State/province [12]
0
0
Santiago
Query!
Country [13]
0
0
Colombia
Query!
State/province [13]
0
0
Barranquilla
Query!
Country [14]
0
0
Colombia
Query!
State/province [14]
0
0
Bogota
Query!
Country [15]
0
0
Croatia
Query!
State/province [15]
0
0
Zagreb
Query!
Country [16]
0
0
Czech Republic
Query!
State/province [16]
0
0
Brno
Query!
Country [17]
0
0
Czech Republic
Query!
State/province [17]
0
0
Havffov
Query!
Country [18]
0
0
Czech Republic
Query!
State/province [18]
0
0
Olomouc
Query!
Country [19]
0
0
Czech Republic
Query!
State/province [19]
0
0
Ostrava-Vitkovice
Query!
Country [20]
0
0
Czech Republic
Query!
State/province [20]
0
0
Ostrava
Query!
Country [21]
0
0
Czech Republic
Query!
State/province [21]
0
0
Praha 5
Query!
Country [22]
0
0
Czech Republic
Query!
State/province [22]
0
0
Praha
Query!
Country [23]
0
0
Czech Republic
Query!
State/province [23]
0
0
Teplice
Query!
Country [24]
0
0
Estonia
Query!
State/province [24]
0
0
Parnu
Query!
Country [25]
0
0
Estonia
Query!
State/province [25]
0
0
Tallinn
Query!
Country [26]
0
0
Estonia
Query!
State/province [26]
0
0
Tartu
Query!
Country [27]
0
0
France
Query!
State/province [27]
0
0
Amiens
Query!
Country [28]
0
0
France
Query!
State/province [28]
0
0
Bouches-du-Rhone
Query!
Country [29]
0
0
France
Query!
State/province [29]
0
0
Clermont-Ferrand
Query!
Country [30]
0
0
France
Query!
State/province [30]
0
0
Nice
Query!
Country [31]
0
0
Georgia
Query!
State/province [31]
0
0
Tbilisi
Query!
Country [32]
0
0
Germany
Query!
State/province [32]
0
0
Bayreuth
Query!
Country [33]
0
0
Germany
Query!
State/province [33]
0
0
Berlin
Query!
Country [34]
0
0
Germany
Query!
State/province [34]
0
0
Erbach
Query!
Country [35]
0
0
Germany
Query!
State/province [35]
0
0
Hannover
Query!
Country [36]
0
0
Germany
Query!
State/province [36]
0
0
Koln
Query!
Country [37]
0
0
Germany
Query!
State/province [37]
0
0
Leipzig
Query!
Country [38]
0
0
Germany
Query!
State/province [38]
0
0
Marberg
Query!
Country [39]
0
0
Germany
Query!
State/province [39]
0
0
Prien
Query!
Country [40]
0
0
Germany
Query!
State/province [40]
0
0
Ulm
Query!
Country [41]
0
0
Germany
Query!
State/province [41]
0
0
Westerstede
Query!
Country [42]
0
0
Greece
Query!
State/province [42]
0
0
Athens
Query!
Country [43]
0
0
Greece
Query!
State/province [43]
0
0
Thessaloniki
Query!
Country [44]
0
0
India
Query!
State/province [44]
0
0
Gujarat
Query!
Country [45]
0
0
India
Query!
State/province [45]
0
0
Madhyr Pradesh
Query!
Country [46]
0
0
India
Query!
State/province [46]
0
0
Maharashtra
Query!
Country [47]
0
0
India
Query!
State/province [47]
0
0
Punjab
Query!
Country [48]
0
0
India
Query!
State/province [48]
0
0
Tamil Nadu
Query!
Country [49]
0
0
India
Query!
State/province [49]
0
0
West Bengal
Query!
Country [50]
0
0
India
Query!
State/province [50]
0
0
Bangalore
Query!
Country [51]
0
0
India
Query!
State/province [51]
0
0
Chennai
Query!
Country [52]
0
0
India
Query!
State/province [52]
0
0
Mangalore
Query!
Country [53]
0
0
India
Query!
State/province [53]
0
0
Navi Mumbai
Query!
Country [54]
0
0
India
Query!
State/province [54]
0
0
New Delhi
Query!
Country [55]
0
0
India
Query!
State/province [55]
0
0
Saket
Query!
Country [56]
0
0
Latvia
Query!
State/province [56]
0
0
Riga
Query!
Country [57]
0
0
Mexico
Query!
State/province [57]
0
0
Aguascalientes
Query!
Country [58]
0
0
Mexico
Query!
State/province [58]
0
0
Chihuahua
Query!
Country [59]
0
0
Mexico
Query!
State/province [59]
0
0
Heroes de Padierna
Query!
Country [60]
0
0
Mexico
Query!
State/province [60]
0
0
Mexico City
Query!
Country [61]
0
0
Mexico
Query!
State/province [61]
0
0
Monterrey
Query!
Country [62]
0
0
Netherlands
Query!
State/province [62]
0
0
Breda
Query!
Country [63]
0
0
Netherlands
Query!
State/province [63]
0
0
Nieuwegein
Query!
Country [64]
0
0
New Zealand
Query!
State/province [64]
0
0
Auckland
Query!
Country [65]
0
0
New Zealand
Query!
State/province [65]
0
0
Christchurch
Query!
Country [66]
0
0
New Zealand
Query!
State/province [66]
0
0
Dunedin
Query!
Country [67]
0
0
Peru
Query!
State/province [67]
0
0
Lima
Query!
Country [68]
0
0
Peru
Query!
State/province [68]
0
0
San Isidro
Query!
Country [69]
0
0
Poland
Query!
State/province [69]
0
0
Bialystok
Query!
Country [70]
0
0
Poland
Query!
State/province [70]
0
0
Bydgoszcz
Query!
Country [71]
0
0
Poland
Query!
State/province [71]
0
0
Gdansk
Query!
Country [72]
0
0
Poland
Query!
State/province [72]
0
0
Katowice
Query!
Country [73]
0
0
Poland
Query!
State/province [73]
0
0
Konskie
Query!
Country [74]
0
0
Poland
Query!
State/province [74]
0
0
Krakow
Query!
Country [75]
0
0
Poland
Query!
State/province [75]
0
0
Lodz
Query!
Country [76]
0
0
Poland
Query!
State/province [76]
0
0
Lublin
Query!
Country [77]
0
0
Poland
Query!
State/province [77]
0
0
Olsztyn
Query!
Country [78]
0
0
Poland
Query!
State/province [78]
0
0
Plewiska
Query!
Country [79]
0
0
Poland
Query!
State/province [79]
0
0
Poznan
Query!
Country [80]
0
0
Poland
Query!
State/province [80]
0
0
Szczecin
Query!
Country [81]
0
0
Poland
Query!
State/province [81]
0
0
Warszawa
Query!
Country [82]
0
0
Poland
Query!
State/province [82]
0
0
Wroclaw
Query!
Country [83]
0
0
Romania
Query!
State/province [83]
0
0
Brasov
Query!
Country [84]
0
0
Romania
Query!
State/province [84]
0
0
Bucharest
Query!
Country [85]
0
0
Romania
Query!
State/province [85]
0
0
Campulung
Query!
Country [86]
0
0
Romania
Query!
State/province [86]
0
0
Sibiu
Query!
Country [87]
0
0
Romania
Query!
State/province [87]
0
0
Targu Mures
Query!
Country [88]
0
0
Russian Federation
Query!
State/province [88]
0
0
Kaluga
Query!
Country [89]
0
0
Russian Federation
Query!
State/province [89]
0
0
Kazan
Query!
Country [90]
0
0
Russian Federation
Query!
State/province [90]
0
0
Kransodar
Query!
Country [91]
0
0
Russian Federation
Query!
State/province [91]
0
0
Kursk
Query!
Country [92]
0
0
Russian Federation
Query!
State/province [92]
0
0
Moscow
Query!
Country [93]
0
0
Russian Federation
Query!
State/province [93]
0
0
Novosibirsk
Query!
Country [94]
0
0
Russian Federation
Query!
State/province [94]
0
0
Perm
Query!
Country [95]
0
0
Russian Federation
Query!
State/province [95]
0
0
Rostov-on-Don
Query!
Country [96]
0
0
Russian Federation
Query!
State/province [96]
0
0
Smolensk
Query!
Country [97]
0
0
Russian Federation
Query!
State/province [97]
0
0
Ufa
Query!
Country [98]
0
0
Serbia
Query!
State/province [98]
0
0
Belgrade
Query!
Country [99]
0
0
Serbia
Query!
State/province [99]
0
0
Kragujevac
Query!
Country [100]
0
0
Serbia
Query!
State/province [100]
0
0
Nis
Query!
Country [101]
0
0
Spain
Query!
State/province [101]
0
0
Cordoba
Query!
Country [102]
0
0
Spain
Query!
State/province [102]
0
0
Madrid
Query!
Country [103]
0
0
Spain
Query!
State/province [103]
0
0
Malaga
Query!
Country [104]
0
0
Spain
Query!
State/province [104]
0
0
Seville
Query!
Country [105]
0
0
Ukraine
Query!
State/province [105]
0
0
Chernivtsi
Query!
Country [106]
0
0
Ukraine
Query!
State/province [106]
0
0
Dnipropetrovsk
Query!
Country [107]
0
0
Ukraine
Query!
State/province [107]
0
0
Donetsk
Query!
Country [108]
0
0
Ukraine
Query!
State/province [108]
0
0
Kharkiv
Query!
Country [109]
0
0
Ukraine
Query!
State/province [109]
0
0
Kyiv
Query!
Country [110]
0
0
Ukraine
Query!
State/province [110]
0
0
Odesa
Query!
Country [111]
0
0
Ukraine
Query!
State/province [111]
0
0
Poltava
Query!
Country [112]
0
0
Ukraine
Query!
State/province [112]
0
0
Simferopol
Query!
Country [113]
0
0
Ukraine
Query!
State/province [113]
0
0
Ternopil
Query!
Country [114]
0
0
Ukraine
Query!
State/province [114]
0
0
Vinnytsya
Query!
Country [115]
0
0
United Kingdom
Query!
State/province [115]
0
0
London
Query!
Country [116]
0
0
United Kingdom
Query!
State/province [116]
0
0
Manchester
Query!
Country [117]
0
0
United Kingdom
Query!
State/province [117]
0
0
Nottingham
Query!
Country [118]
0
0
United Kingdom
Query!
State/province [118]
0
0
Sheffield
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Biogen
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The primary objective of this study is to evaluate the long-term safety and tolerability of
peginterferon beta-1a (BIIB017) in participants originally treated in Study 105MS301
(NCT00906399) who continue peginterferon beta-1a treatment. The secondary objective of this
study is to describe long-term multiple sclerosis (MS) outcomes in participants originally
treated in Study 105MS301 (NCT00906399) who continue peginterferon beta-1a treatment.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01332019
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Medical Director
Query!
Address
0
0
Biogen
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01332019
Download to PDF